Basic Information
| LncRNA/CircRNA Name | circSMAD2 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular cancer |
| ICD-0-3 | NA |
| Methods | qPCR, western blot, luciferase reporter assay, RIP, other |
| Sample | HCC tissues and cell lines (HepG2, HCCLM9, HCCLM3, and MHCC97L) |
| Expression Pattern | down-regulated |
| Function Description | The in vitro experiments showed that overexpressed circSMAD2 inhibited the migration, invasion, and epithelial-mesenchymal transition (EMT) in HCC cells. Bioinformatics predicted that miR-629 is a potential target of circSMAD2, and the dual-luciferase reporter assay verified that miR-629 directly bound circSMAD2. In addition, we found that overexpression of circSMAD2 suppressed the expression of miR-629 in HCC cells, whereas knockdown of circSMAD2 upregulated the expression of miR-629. Furthermore, co-transfection of miR-629 mimics with circSMAD2 reversed the circSMAD2 effects of inhibiting the migration, invasion, and EMT of HCC cells. |
| Pubmed ID | 29844683 |
| Year | 2018 |
| Title | circSMAD2 Inhibits the Epithelial-Mesenchymal Transition by Targeting miR-629 in Hepatocellular Carcinoma |
External Links
| Links for circSMAD2 | GenBank HGNC NONCODE |
| Links for hepatocellular cancer | OMIM COSMIC |